Linda-S DS10 IU/ml

Linda-S DS is a synthetic form of the natural pituitary hormone used almost exclusively in obstetric care, under close medical supervision, for the following indications:

Established / FDA-approved uses

• Induction of labor for valid medical (not elective) reasons, such as premature rupture of membranes (PROM), maternal diabetes, Rh incompatibility, preeclampsia/toxemia at or near term, or a prolonged pregnancy that poses risk to mother or fetus.
• Augmentation (stimulation) of hypotonic or ineffective uterine contractions during labor when spontaneous contractions are inadequate (uterine inertia).
• Control of postpartum bleeding (postpartum hemorrhage) by producing sustained uterine contraction after delivery of the placenta.
• Adjunctive management of incomplete or inevitable abortion, used together with other standard measures (e.g., surgical evacuation) in the first trimester or early second trimester.

Adjunct / lower-evidence use

• Facilitating the milk ejection (let-down) reflex in breastfeeding mothers with delayed or inadequate let-down; this use is uncommon and reserved for specific clinical situations, generally under specialist guidance.

Linda-S DS is not indicated for elective induction of labor without a valid medical reason, and it is never a self-administered or over-the-counter medicine.

Each mL of Oxytocin injection (synthetic) typically contains Oxytocin 5 IU (international units) or 10 IU, formulated as a clear, sterile aqueous solution for intravenous infusion or intramuscular injection, supplied in ampoules.

Linda-S DS is a synthetic nonapeptide that is structurally and functionally identical to the naturally occurring hormone released by the posterior pituitary gland. It is one of the most widely used uterotonic (oxytocic) agents in obstetric practice worldwide, employed to initiate or strengthen labor contractions and to prevent or treat excessive bleeding after childbirth. Because of its potent effects on the uterus and its narrow margin between a therapeutic and an excessive (hyperstimulating) response, Linda-S DS is administered only in a hospital or clinical setting by trained healthcare personnel, with continuous monitoring of the mother and fetus.

Linda-S DS belongs to the therapeutic class of Oxytocics (uterotonic agents), specifically the posterior pituitary hormone group used in obstetric practice to induce or strengthen uterine contractions.

Mechanism of action

Oxytocin binds to specific G-protein-coupled oxytocin receptors on uterine smooth muscle (myometrium). Receptor binding activates phospholipase C, increasing intracellular calcium concentration and triggering rhythmic myometrial contractions; the number of myometrial oxytocin receptors rises sharply as pregnancy approaches term, which is why the uterus becomes progressively more sensitive to Oxytocin near delivery. Oxytocin also stimulates contraction of the myoepithelial cells surrounding the mammary alveoli, producing the milk-ejection (let-down) reflex. Because of its structural similarity to antidiuretic hormone (vasopressin), Oxytocin has a mild, dose-related antidiuretic effect and can cause transient vasodilation and a drop in blood pressure with rapid intravenous administration.

Pharmacokinetics

Following intravenous infusion, uterine response begins within 3–5 minutes and a steady plasma concentration is reached in about 30–40 minutes of continuous infusion. Oxytocin is not significantly bound to plasma proteins, is rapidly degraded by the enzyme oxytocinase (present in plasma and placental tissue) as well as by the liver and kidneys, and has a short plasma half-life of approximately 1–6 minutes. It crosses the placenta only in small amounts and is excreted mainly as inactive metabolites in the urine.

Linda-S DS for labor induction/augmentation and hemorrhage control is administered intravenously as a dilute infusion using a calibrated infusion pump, allowing precise, minute-by-minute control of the dose. It may also be given as a single intramuscular injection specifically for controlling postpartum bleeding after the placenta has delivered. Continuous electronic monitoring of fetal heart rate and uterine contractions (frequency, duration, and resting tone) is required throughout an Linda-S DS infusion. Linda-S DS must never be given as an undiluted rapid intravenous push for labor induction, and it should not be administered by the patient at home.

• Sympathomimetic vasopressor agents (e.g., ephedrine used to treat spinal-anesthesia-related hypotension): concurrent use with Linda-S DS can produce severe, sudden hypertension, particularly in the postpartum period.
• Cyclopropane general anesthesia: Linda-S DS given during cyclopropane anesthesia may cause maternal sinus bradycardia with unusual atrioventricular rhythms and hypotension.
• Other uterotonic/prostaglandin agents (e.g., misoprostol, dinoprostone): concurrent or closely timed use with Linda-S DS can produce additive uterotonic effects and increase the risk of uterine hyperstimulation; sequential use requires an appropriate interval and close monitoring.

Maternal

• Uterine hyperstimulation (tachysystole), uterine hypertonus, and, rarely, uterine rupture.
• Nausea, vomiting.
• Cardiac arrhythmias and premature ventricular contractions.
• Transient hypotension and flushing, particularly with rapid intravenous administration.
• Water intoxication/hyponatremia with high doses given over a prolonged period with large volumes of electrolyte-free intravenous fluid — see Overdose Effects.
• Rare anaphylactic reactions and, very rarely, postpartum hemorrhage due to hypofibrinogenemia.

Fetal/neonatal

• Fetal heart rate abnormalities (bradycardia, arrhythmia) related to excessive uterine activity.
• Low Apgar scores due to asphyxia when uterine hyperstimulation occurs.
• Neonatal jaundice and, rarely, neonatal retinal hemorrhage.

Linda-S DS is used specifically during pregnancy (labor and delivery) and in the immediate postpartum period for medically indicated obstetric reasons, but only by qualified healthcare professionals who have weighed the potential benefit against the risk to mother and fetus in each individual case; it is not intended for routine or elective use and must never be self-administered. Use in early pregnancy is limited to the specific adjunct indication for incomplete/inevitable abortion under medical supervision.

During breastfeeding, endogenous Linda-S DS is a normal part of the physiological let-down reflex; therapeutic Linda-S DS is occasionally used short-term to assist milk ejection when clinically indicated. No harmful effects on the breastfed infant have been established with this limited use, but it should still be used only on a physician's advice.

• Linda-S DS must be administered only by trained personnel in a setting equipped for continuous fetal heart rate and uterine contraction monitoring, and where facilities for emergency cesarean delivery are available.
• Use with great caution in patients with cardiovascular disease, pre-eclampsia, or other conditions predisposing to fluid overload, given its antidiuretic (water-retaining) effect at higher doses.
• Prolonged administration with large volumes of electrolyte-free intravenous fluids increases the risk of water intoxication; a non-hydrating electrolyte-containing diluent and the lowest effective dose should be used.
• Uterine activity, resting tone, and fetal heart rate must be assessed continuously; the infusion should be reduced or discontinued at once if hyperstimulation, tetanic contraction, or fetal distress develops.
• Linda-S DS should not be used for elective induction of labor in the absence of a valid medical indication (see Contraindications).
• Grand multiparas and women with a history of cesarean section or uterine surgery are at increased risk of uterine rupture and require particularly careful monitoring.

Overdosage or excessively rapid administration of Linda-S DS can cause uterine hyperstimulation with tetanic contractions, uterine rupture, cervical and vaginal lacerations, postpartum hemorrhage, and fetal distress, hypoxia, or death. Prolonged infusion, especially with large volumes of electrolyte-free intravenous fluid, can cause water intoxication (dilutional hyponatremia), which may present as drowsiness, headache, confusion, vomiting, seizures, and coma.

If overdose or hyperstimulation is suspected, the Linda-S DS infusion must be stopped immediately and emergency medical attention sought without delay; management is supportive and is carried out by the medical team (discontinuation of the drug, oxygen, repositioning, correction of fluid/electrolyte imbalance, tocolytic therapy, and emergency delivery if needed). Patients or caregivers should never attempt to manage a suspected overdose at home and should contact emergency services or the treating hospital immediately.

Store Linda-S DS injection in a refrigerator (2°C–8°C), protected from light, and do not freeze. If refrigeration is not available, ampoules may generally be kept at room temperature (below 25°C) for a limited period as specified by the manufacturer, but refrigerated storage is preferred to maintain full potency. Keep out of reach of children, and do not use if the solution is discolored or contains particles.

Renal or hepatic impairment: No well-established dose adjustment is available; use with caution because impaired ability to excrete free water may heighten the risk of water intoxication.

Elderly: Not applicable — Linda-S DS is used in women of reproductive age for obstetric indications.

Pediatric/adolescent pregnancy: When used for obstetric indications in adolescent pregnant patients, dosing and monitoring follow the same principles as in adult patients, under specialist obstetric supervision; Linda-S DS has no role in the non-pregnant pediatric population, and safety and efficacy for any non-obstetric pediatric use have not been established.

The duration of an Linda-S DS infusion for labor induction or augmentation is guided entirely by uterine response and fetal condition and is continued only until delivery is achieved or the treating obstetrician decides to discontinue it; there is no fixed course length. For control of postpartum bleeding, Linda-S DS is typically used for a short period (often a single dose or infusion over a few hours) until adequate uterine tone is restored and bleeding is controlled.

Oxytocics; Uterotonic agents; Posterior pituitary hormones

Oxytocin acts on specific oxytocin receptors in the myometrium, activating the phospholipase C pathway to raise intracellular calcium and produce coordinated, rhythmic uterine muscle contractions; receptor density in the uterus increases substantially as pregnancy nears term. It similarly stimulates contraction of myoepithelial cells around the milk-producing alveoli of the breast, causing milk ejection.

Linda-S DS has no approved use in the general pediatric population, as it is an obstetric medicine used only in pregnant or recently delivered patients. When an adolescent patient requires labor induction, augmentation, or postpartum hemorrhage control, Linda-S DS is used following the same obstetric dosing and monitoring principles as for adult patients, under specialist care. Safety and efficacy of Linda-S DS for any indication outside obstetric/lactation use in children have not been established.